BioSite, Eli Lilly To Team Up For More Personalized Sepsis Therapy
This article was originally published in The Gray Sheet
Executive Summary
BioSite is working to get 510(k) clearance for a new point-of-care diagnostic in time to participate in a clinical trial of Eli Lilly's sepsis therapy drug Xigris, Biosite said March 20. The trial is scheduled to begin later this year
You may also be interested in...
Monogram Launches Companion Diagnostic To Pfizer’s New HIV Drug
South San Francisco-based Monogram Biosciences launched its Trofile HIV diagnostic Aug. 6, timed with FDA approval of Pfizer's first-in-class HIV drug Selzentry (maraviroc) the same day
Monogram Launches Companion Diagnostic To Pfizer’s New HIV Drug
South San Francisco-based Monogram Biosciences launched its Trofile HIV diagnostic Aug. 6, timed with FDA approval of Pfizer's first-in-class HIV drug Selzentry (maraviroc) the same day
FDA Adjusts Thinking On Drug/Diagnostic Co-Development Draft Guidance
FDA will be more flexible about the schedule it expects sponsors to follow for drug/diagnostic co-development than the agency suggested in a 2005 "concept paper" on the subject